Breaking Finance News

Antares Pharma Inc (NASDAQ:ATRS) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Antares Pharma Inc (NASDAQ:ATRS) to Hold in a statement released on 10/11/2016.

On 3/30/2016, Jefferies & Co released a statement for Antares Pharma Inc (NASDAQ:ATRS) bumped down the target price from $5.00 to $3.00 that suggested an upside of 2.61%.

Boasting a price of $1.78, Antares Pharma Inc (NASDAQ:ATRS) traded -1.11% lower on the day. With the last stock price close up 58.85% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Antares Pharma Inc has recorded a 50-day average of $1.51 and a two hundred day average of $1.12. Volume of trade was down over the average, with 579,111 shares of ATRS changing hands under the typical 794,174

Performance Chart

Antares Pharma Inc (NASDAQ:ATRS)

With a total market value of $0, Antares Pharma Inc has with a one year low of $0.67 and a one year high of $1.85 .

A total of 5 equity analysts have released a ratings update on ATRS. Three equity analysts rating the company a strong buy, one equity analyst rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $4.50.

Brief Synopsis About Antares Pharma Inc (NASDAQ:ATRS)

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *